References

1. Malakoff, D., The rise of the mouse, biomedicine's model mammal, Science, 288, 248-253, 2000.

2. Koch, R., Die Aetiologie der Milzbrand-Krankheit, begrundet auf die Entwicklungsgeschichte des Bacillus anthracis, Beitr Biol Pflanz, 2, 277-310, 1877.

3. Jenner, E., An inquiry into the causes and effects of the variolae vaccine, London, Samson, Low, 1798.

4. Meslin, F., Fishbein, D., and Matter, H., Rationale and prospects for rabies elimination in developing countries, Current Topics in Microbiology and Immunology, 187, 1-26, 1994.

5. Hendriksen, C., A short history of the use of animals in vaccine development and quality control, Dev Biol Stand, 86, 3-10, 1996.

6. Kohler, G. and Milstein, C., Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion, Eur J Immunol, 6, 511-519, 1976.

7. Russell, E., Smith, L., and Lawson, F., Implantation of normal blood-forming tissue in radiated genetically anemic hosts, Science, 124, 1076-1077, 1956.

8. Culliton, B., Nobelists back animal research, Science, 244, 524, 1989.

9. Bradley, A., Evans, M., Kaufman, M., and Robertson, E., Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines, Nature, 309, 255-256, 1984.

10. Thomas, K. and Capecchi, M., Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells, Cell, 6, 503-512, 1987.

11. Zhou, L., Dey, C., Wert, S., DuVall, M., Frizzell, R., and Whitsett, J., Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR, Science, 266, 1705-1708, 1994.

12. Larson, J., Delcarpio, J., Farberman, M., Morrow, S., and Cohen, J., CFTR modulates lung-secretory cell proliferation and differentiation, Am J Physiol Lung Cell Mol Physiol, 279, L333-41, 2000.

13. Leppanen, P., Luoma, J., Hofker, M., Havekes, L., and Yla-Herttuala, S., Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice, Atherosclerosis, 136, 147-152, 1998.

14. Shibata, N., Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation, Neuropathology, 21, 82-92, 2001.

15. Levine, M., Klapstein, G., Koppel, A., Cepeda, C., Vargas, M., Jokel, E., Carpenter, E., Zanjani, H., Hurst, R., Efstratiadis, A., Zeitlin, S., and Chesselet, M., Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knocking mouse models of Huntington's disease, J Neurosci Res 58, 515-32, 1999.

16. Zhang, Z., Liu, Q., Lantry, L., Wang, Y., Kelloff, G., Anderson, M., Wiseman, R., Lubet, R., and You, M., A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethason/myo-inositol and chemotherapeutic agents taxol or adriamycin, Cancer Res, 60, 901-907, 2000.

17. Washington Fax, Celera completes 99% of the mouse genome (Genomics comply looks ahead to next stage - annotation), Washington Fax, May 4, 2001.

18. Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., et al. The sequence of the human genome, Science, 291, 1304-1351, 2001.

19. Nadeau, J.H., Balling, R., Barsh, G., Beier, D., and Brown, S.D.M., Functional annotation of mouse genome sequence, Science, 291, 1251-1255, 2001.

20. Washington Fax, Public - private mouse-sequencing consortium completes mouse genome (Complete sequence will be released to researchers worldwide), Washington Fax, May 10, 2001.

21. Rogers, J.R. and Bradley, A., The mouse genome sequence: status and prospects, Genomics, 77, 117-118, 2001.

0 0

Post a comment